TP53 and B-cell chronic lymphocytic leukemia: The introduction of effective mechanism-based treatment (i.e. ibrutinib, idelalisib, venetoclax) significantly improved the outcome of CLL [11–13] and the adverse impact of 17p-/TP53 mutation and of the IGHV mutational status were found to be attenuated in several studies [14–16].